Tevogen Bio Holdings(TVGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TVGN Tevogen Bio Holdings

盘前交易 08-20 05:39:26 EDT

6.42

+0.11

+1.74%

最高6.50	最低6.00	成交量9,112
今开6.50	昨收6.31	日振幅7.92%
总市值4,180万	流通市值2,401万	总股本651.15万
成交额5.70万	换手率0.24%	流通股本374.05万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":6.42,"timestamp":1787169600000,"preClose":6.31,"halted":0,"volume":9112,"delay":0,"changeRate":0.017432646592710037,"floatShares":3740500,"shares":6511540,"eps":-6.322108,"marketStatus":"盘前交易","change":0.11,"latestTime":"08-20 05:39:26 EDT","open":6.5,"high":6.5,"low":6,"amount":57030.142773600004,"amplitude":0.079239,"askPrice":7.48,"askSize":100,"bidPrice":5.9,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-6.322108,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787232600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":6.42,"postHourTrading":{"tag":"盘后","latestPrice":6.42,"preClose":6.42,"latestTime":"19:53 EDT","volume":24,"amount":154.08,"timestamp":1787183609207,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.108165287036153},"requestUrl":"/m/hq/s/TVGN","defaultTab":"news","newsList":[{"id":"1158208860","title":"Tevogen推进战略收购计划，有望支持合计约1亿美元年收入","url":"https://stock-news.laohu8.com/highlight/detail?id=1158208860","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158208860?lang=zh_cn&edition=full","pubTime":"2026-05-29 00:34","pubTimestamp":1779986054,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings正积极推进其战略收购计划。这一系列举措有望为公司带来合计约1亿美元的年收入潜力。该战略旨在通过收购整合，拓展业务版图并增强市场竞争力。公司管理层表示，相关计划正在稳步实施中，未来将进一步披露具体进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","TVGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164018279","title":"Tevogen Bio Holdings签署意向书，评估收购管理服务组织的可能性","url":"https://stock-news.laohu8.com/highlight/detail?id=1164018279","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164018279?lang=zh_cn&edition=full","pubTime":"2026-05-22 00:15","pubTimestamp":1779380114,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings已签署一份意向书，旨在评估对一家管理服务组织进行潜在收购的可能性。此举标志着该公司在探索新的业务增长路径和扩展其服务范围方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","TVGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163602362","title":"新闻稿：Tevogen Bio Holdings宣布获得300万美元私募投资，每股8美元，较最新收盘价溢价14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163602362","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163602362?lang=zh_cn&edition=full","pubTime":"2026-05-12 23:49","pubTimestamp":1778600957,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc.  今日宣布，已与现有投资者The Patel Family, LLP达成一项证券购买协议，通过公开市场私募投资方式进行融资，总收益为300万美元。公司计划将此次PIPE融资所得用于支持持续运营、推进战略性增长计划以及一般公司用途。根据证券购买协议条款，Tevogen将发行375,000份预注资认股权证，每份权证可行使以购买一股公司普通股。此次PIPE融资的定价为每份预注资认股权证8.00美元，这较公司股票在2026年5月11日的收盘价有14%的溢价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4588","TM","BK4139","BK4604","03160","BK4585","BK4555","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100801315","title":"Tevogen Bio宣布以每股8美元完成300万美元私募融资，较最新收盘价溢价14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100801315","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100801315?lang=zh_cn&edition=full","pubTime":"2026-05-12 23:46","pubTimestamp":1778600791,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings 宣布，已成功完成一笔总额为300万美元的私募股权融资。此次融资的每股定价为8美元，这一价格相较于公司股票在公开市场的最新收盘价，呈现出显著的14%溢价。\n这笔交易不仅为公司注入了新的发展资金，更以高于市场的价格完成，凸显了特定投资方对公司未来前景的认可与信心。在当前市场环境下，以溢价进行私募融资，往往被视作一个积极的信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179355179","title":"Tevogen Bio Holdings：新业务机遇预计每年贡献超2000万美元收入 明年起助推两位数增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1179355179","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179355179?lang=zh_cn&edition=full","pubTime":"2026-03-27 00:48","pubTimestamp":1774543689,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings宣布其新业务线预计将带来显著财务贡献，年收入有望增加超过2000万美元。这一增长动力预计将从明年开始，持续推动公司实现两位数的高增速扩张。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141813665","title":"Tevogen推进战略CRO评估，拓展临床研究交付能力并驱动收入增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1141813665","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141813665?lang=zh_cn&edition=full","pubTime":"2026-03-27 00:47","pubTimestamp":1774543631,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings（简称Tevogen）正积极推进其战略性的合同研究组织（CRO）评估进程，旨在进一步扩展公司的临床研究服务交付能力，并为持续的收入增长注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165653461","title":"Tevogen.AI 宣布 Predictcell™ Beta 版取得新进展，精准度指标提升并扩展专有AI基础设施","url":"https://stock-news.laohu8.com/highlight/detail?id=1165653461","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165653461?lang=zh_cn&edition=full","pubTime":"2026-03-14 00:31","pubTimestamp":1773419470,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings (TVGN) 近日披露了其人工智能平台 Predictcell™ Beta 版本的多项重要进展。该版本在精准度指标上展现出显著优化，同时公司还进一步扩展了其专有的AI基础设施架构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","TVGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123137439","title":"Tevogen Bio Holdings 评估收购 Sciometrix 及 Clinicus 平台以监测长期新冠症状","url":"https://stock-news.laohu8.com/highlight/detail?id=1123137439","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123137439?lang=zh_cn&edition=full","pubTime":"2026-03-12 03:16","pubTimestamp":1773256571,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. 正在考虑收购 Sciometrix 和 Clinicus 平台，旨在加强对长期新冠（Long Covid）的监测能力。此举显示该公司正积极拓展其在生物科技领域的布局，特别是在应对新冠后遗症方面寻求新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","TVGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618118139","title":"Tevogen Bio Holdings Inc.盘中异动 快速跳水5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618118139","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618118139?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:41","pubTimestamp":1773236461,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日21时41分，Tevogen Bio Holdings Inc.股票出现波动，股价快速跳水5.01%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.35%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司，利用CD8细胞毒性T淋巴细胞，开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311214101a6b84e82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311214101a6b84e82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TVGNW","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135990684","title":"Tevogen推进仿制药战略，签署意向书评估收购Apozeal制药的潜在可能","url":"https://stock-news.laohu8.com/highlight/detail?id=1135990684","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135990684?lang=zh_cn&edition=full","pubTime":"2026-03-06 03:51","pubTimestamp":1772740289,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings（简称Tevogen）近日在仿制药业务布局上迈出关键一步，公司已签署意向书，正式启动对Apozeal制药的潜在收购评估。此举标志着Tevogen正加速拓展其仿制药产品线，以强化在生物医药领域的市场竞争力。通过本次战略评估，Tevogen有望进一步整合行业资源，提升其在全球仿制药市场的份额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139","TVGNW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146346246","title":"Tevogen Bio Holdings Inc 正积极考虑其他交易，重点聚焦生命科学相关业务","url":"https://stock-news.laohu8.com/highlight/detail?id=1146346246","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146346246?lang=zh_cn&edition=full","pubTime":"2026-03-06 03:51","pubTimestamp":1772740274,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc 目前正积极评估其他交易机会，并将战略重点明确锁定在生命科学领域的相关业务上。公司此举旨在进一步拓展其在生物科技行业的影响力，并探索潜在的协同增长机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGNW","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106152731","title":"Tevogen Bio Holdings签署意向书 拟评估收购Sciometrix及其数字护理管理平台Clinicus","url":"https://stock-news.laohu8.com/highlight/detail?id=1106152731","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106152731?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:20","pubTimestamp":1772115616,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings已签署意向书，正就潜在收购医疗科技公司Sciometrix及其创新数字护理管理平台Clinicus展开评估。此次战略举措旨在整合Clinicus的智能化患者管理技术，强化Tevogen在精准医疗领域的数字化服务能力。\n该平台通过人工智能驱动的远程监测系统，可实现个性化治疗方案的动态优化。若交易顺利完成，将显著提升Tevogen在细胞疗法商业化过程中的患者全周期管理效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139","TVGNW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518527981","title":"Tevogen Bio Holdings Inc.盘中异动 早盘快速下跌5.18%报1.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518527981","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518527981?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:01","pubTimestamp":1741618870,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日23时01分，Tevogen Bio Holdings Inc.股票出现波动，股价快速跳水5.18%。截至发稿，该股报1.08美元/股，成交量11.0718万股，换手率0.06%，振幅5.27%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.44%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 一家临床阶段的专业免疫治疗公司，利用 CD8+ 细胞毒性 T 淋巴细胞开发现成的精准 T 细胞疗法，用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031023011198a2b2d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031023011198a2b2d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGN","TVGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517940697","title":"Tevogen Bio Holdings Inc.盘中异动 快速跳水5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517940697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517940697?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:48","pubTimestamp":1741196930,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时48分，Tevogen Bio Holdings Inc.股票出现波动，股价大幅下挫5.35%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体涨幅为1.20%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 一家临床阶段的专业免疫治疗公司，利用 CD8+ 细胞毒性 T 淋巴细胞开发现成的精准 T 细胞疗法，用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306014850abe9e98d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306014850abe9e98d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGNW","TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677087","title":"Tevogen Bio Holdings Inc.盘中异动 早盘大幅拉升5.93%报1.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677087","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677087?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:47","pubTimestamp":1741099627,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时47分，Tevogen Bio Holdings Inc.股票出现异动，股价大幅上涨5.93%。截至发稿，该股报1.25美元/股，成交量15.5608万股，换手率0.09%，振幅3.39%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.45%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 一家临床阶段的专业免疫治疗公司，利用 CD8+ 细胞毒性 T 淋巴细胞开发现成的精准 T 细胞疗法，用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503042247089639497e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503042247089639497e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGNW","TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516655652","title":"Tevogen Bio Holdings Inc.盘中异动 股价大跌5.08%报1.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516655652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516655652?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:06","pubTimestamp":1741025204,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时06分，Tevogen Bio Holdings Inc.股票出现异动，股价快速下挫5.08%。截至发稿，该股报1.22美元/股，成交量58.3924万股，换手率0.33%，振幅8.20%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.23%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 一家临床阶段的专业免疫治疗公司，利用 CD8+ 细胞毒性 T 淋巴细胞开发现成的精准 T 细胞疗法，用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304020644989a40df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304020644989a40df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGN","TVGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514387794","title":"Tevogen Bio Holdings Inc.盘中异动 临近午盘股价大涨6.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514387794","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514387794?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:41","pubTimestamp":1740674462,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时41分，Tevogen Bio Holdings Inc.股票出现异动，股价急速拉升6.43%。截至发稿，该股报1.32美元/股，成交量15.4541万股，换手率0.09%，振幅4.44%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 一家临床阶段的专业免疫治疗公司，利用 CD8+ 细胞毒性 T 淋巴细胞开发现成的精准 T 细胞疗法，用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022800410398952a4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022800410398952a4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGN","TVGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514011891","title":"Tevogen Bio Holdings Inc.盘中异动 急速跳水5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514011891","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514011891?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:18","pubTimestamp":1740500335,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时18分，Tevogen Bio Holdings Inc.股票出现波动，股价大幅跳水5.44%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.59%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 一家临床阶段的专业免疫治疗公司，利用 CD8+ 细胞毒性 T 淋巴细胞开发现成的精准 T 细胞疗法，用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001855abdc97ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001855abdc97ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGN","TVGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513187720","title":"Tevogen Bio Holdings Inc.盘中异动 早盘大幅下跌5.89%报1.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513187720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513187720?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:02","pubTimestamp":1740409333,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时02分，Tevogen Bio Holdings Inc.股票出现异动，股价急速跳水5.89%。截至发稿，该股报1.33美元/股，成交量16.2036万股，换手率0.09%，振幅4.95%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.24%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 一家临床阶段的专业免疫治疗公司，利用 CD8+ 细胞毒性 T 淋巴细胞开发现成的精准 T 细胞疗法，用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230213962ea093&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230213962ea093&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGN","BK4139","TVGNW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513294469","title":"Tevogen Bio Holdings Inc.盘中异动 早盘股价大跌5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513294469","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513294469?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:33","pubTimestamp":1740151998,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时33分，Tevogen Bio Holdings Inc.股票出现异动，股价急速跳水5.48%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.09%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 一家临床阶段的专业免疫治疗公司，利用 CD8+ 细胞毒性 T 淋巴细胞开发现成的精准 T 细胞疗法，用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221233318abd7bd64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221233318abd7bd64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGN","TVGNW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tevogen.com","stockEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":0.6504},{"period":"3month","weight":-0.4449},{"period":"6month","weight":-0.5427},{"period":"1year","weight":-0.862},{"period":"ytd","weight":-0.6122}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tevogen Inc.于2021年4月21日在开曼群岛注册成立，后合并重组为特拉华州公司。Tevogen是一家临床阶段的专业免疫疗法公司，利用自然界最强大的免疫武器之一—CD8 +细胞毒性T淋巴细胞，开发现成的、未经基因改造的精准T细胞疗法，用于治疗传染病、癌症和神经系统疾病，旨在解决大量患者群体的重大未满足需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.040664},{"month":2,"riseRate":0.6,"avgChangeRate":0.049009},{"month":3,"riseRate":0.4,"avgChangeRate":-0.264435},{"month":4,"riseRate":0.6,"avgChangeRate":-0.057531},{"month":5,"riseRate":0.4,"avgChangeRate":0.045094},{"month":6,"riseRate":0.2,"avgChangeRate":-0.084873},{"month":7,"riseRate":0.6,"avgChangeRate":-0.013744},{"month":8,"riseRate":0.4,"avgChangeRate":-0.069194},{"month":9,"riseRate":0.5,"avgChangeRate":-0.105281},{"month":10,"riseRate":0.75,"avgChangeRate":1.418967},{"month":11,"riseRate":0.5,"avgChangeRate":-0.189646},{"month":12,"riseRate":0.5,"avgChangeRate":-0.111833}],"exchange":"NASDAQ","name":"Tevogen Bio Holdings","nameEN":"Tevogen Bio Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tevogen Bio Holdings(TVGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tevogen Bio Holdings(TVGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tevogen Bio Holdings,TVGN,Tevogen Bio Holdings股票,Tevogen Bio Holdings股票老虎,Tevogen Bio Holdings股票老虎国际,Tevogen Bio Holdings行情,Tevogen Bio Holdings股票行情,Tevogen Bio Holdings股价,Tevogen Bio Holdings股市,Tevogen Bio Holdings股票价格,Tevogen Bio Holdings股票交易,Tevogen Bio Holdings股票购买,Tevogen Bio Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tevogen Bio Holdings(TVGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tevogen Bio Holdings(TVGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}